Fundraising Fox
Spruce Biosciences
NASDAQ: SPRBSouth San Francisco, US · Founded 2016 · Delaware corporation · 37 employees on LinkedIn · 10 known investors
Find your way into Spruce Biosciences
Sign up to see every warm intro you have to Spruce Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Spruce Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B). The company works with patients and families affected by rare neurological conditions.
Founders & leadership
Board
Investors · 10
How we know: Aisling Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: HealthCap's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$191.6M disclosed across 3 of 5 rounds · 1900–2026
▶$50MraisedOct 2025 · 21 investors · BiotechnologyRule 506(b)
- Kirk WaysDirector
- Javier SzwarcbergExecutive Officer, Director
- Simpson CamillaDirector
- Percival Barretto-KoDirector
- Tiba AynechiDirector
- Samir GharibExecutive Officer
- Bali MuralidharDirector
- Michael GreyExecutive Officer, Director
- Daniel SpiegelmanDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $3M
- Placement agents
- Citizens JMP Securities, LLC, H.C. Wainwright & Co., LLC, Leerink Partners LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$53.6MraisedFeb 2023 · 20 investors · BiotechnologyRule 506(b)
- Daniel SpiegelmanDirector
- Javier SzwarcbergExecutive Officer, Director
- Dina ChayaDirector
- Tiba AynechiDirector
- Samir GharibExecutive Officer
- Kirk WaysDirector
- Simpson CamillaDirector
- Bali MuralidharDirector
- Ralph William Charlton IIIExecutive Officer
- Michael GreyExecutive Officer, Director
- Offering amount
- $53.6M
- Amount sold
- $53.6M
- Sales commissions
- $2.4M
- Placement agents
- SVB Securities LLC
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$88MraisedAug 2020 · 11 investors · BiotechnologyRule 506(c)
- SAMIR GHARIBExecutive Officer
- RICHARD KINGExecutive Officer, Director
- TIBA AYNECHIDirector
- CAMILLA SIMPSONDirector
- NIALL O'DONNELLDirector
- JONAS HANSSONDirector
- BALI MURALIDHARDirector
- MICHAEL GREYDirector
- DINA CHAYADirector
- Offering amount
- $88M
- Amount sold
- $88M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Spruce Biosciences do?
- Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B). The company works with patients and families affected by rare neurological conditions.
- Who are Spruce Biosciences's investors?
- Spruce Biosciences's investors include Aisling Capital, HealthCap, RiverVest Venture Partners, Abingworth, Norwest Venture Partners, Novo Holdings, Omega Funds, OrbiMed.
- How much funding has Spruce Biosciences raised?
- Spruce Biosciences has disclosed $191.6M raised across 3 of its 5 known rounds.
- Where is Spruce Biosciences headquartered?
- Spruce Biosciences is headquartered in South San Francisco, US.